Argenx, a biopharmaceutical company with a market capitalisation near $60 billion, has caught the attention of Wall Street analysts. Ten analysts predict the biotech stock will reach at least $1,200 over the next 12 months, up from around $919 as of 2 October 2026. Wells Fargo and UBS set the highest price targets at $1,415 and $1,400 respectively, representing potential gains exceeding 50%. The average price target amongst 21 analysts stands at approximately $1,182, suggesting 29% upside. All but one analyst recommends buying the stock. Argenx's optimism stems from strong performance, delivering $1.5 billion in global product net sales last quarter, up 60% year over year. Its flagship drugs Vyvgart and Vyvgart Hytrulo drive growth, with additional approvals for autoimmune diseases potentially forthcoming.

argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026. 09/30/2026 Key Takeaways * argenx will present data on its portfolio and pipeline at the AANEM Annual Meeting and the MGFA Scientific Session, September 29 to October 2 in Orlando, Florida, including four oral presentations and dozens of posters. * New VYVGART (efgartigimod) results include deepening improvement in ocular myasthenia gravis (MG), sustained one-year efficacy in anti-AChR antibody-negative generalized MG (gMG), real-world data on earlier treatment, and long-term and switch data in chronic inflammatory demyelinating polyneuropathy (CIDP). * argenx will also present Phase 2 empasiprubart data in multifocal motor neuropathy (MMN) and Phase 1b adimanebart data in DOK7 congenital myasthenic syndrome (CMS). argenx, an Amsterdam-based immunology company, announced it will present clinical, long-term, and real-world data for VYVGART (intravenous efgartigimod alfa-fcab) and VYVGART Hytrulo (subcutaneous efgartigimod alfa and hyaluronidase-qvfc), along with results for two pipeline candidates. Chief Medical Officer Luc Truyen, M.D., Ph.D., said the data show how far the evidence for VYVGART reaches, across years of treatment and into patient populations historically left out of clinical trials. In MG, the company will present three sets of findings: * Ocular MG. In the Phase 3 ADAPT OCULUS study, patient-reported ocular scores on the Myasthenia Gravis Impairment Index (MGII) improved further after two VYVGART cycles beyond the placebo-controlled period. Scores went from -4.5 to -6.8 points in patients with anti-AChR antibodies and from -2.7 to -4.5 points in triple-seronegative patients. The company says the results build on evidence for VYVGART's potential as the first targeted treatment for ocular MG.

Argenx stock has gained roughly 14% year-to-date, with Wall Street analysts projecting a potential 23% upside over the next 12 months. The biotech company has delivered 18 consecutive quarters of revenue growth. In Q2 2026, Argenx's global product net sales surged 60% year over year to $1.5 billion, with a 17% quarter-over-quarter increase. The Vyvgart franchise, treating chronic autoimmune disorders, drives growth following May 2026 FDA approval making it the first treatment for all serotypes of adults with generalised myasthenia gravis. Approximately 24,000 US patients receive treatment for chronic inflammatory demyelinating polyneuropathy, with half not well-managed on current therapy. Argenx reported positive Phase 3 results for Vyvgart in ocular myasthenia gravis earlier this year, with regulatory filing underway.